LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

Merck stock slid Tuesday after the company’s earnings failed to ease growing worries about the impending expiration of the ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Eli Lilly's bottom line for 2022 was more than $6 billion, practically the same as the amount it made in 2020. But don't let that trick you into thinking it won't be adding more earnings. It ...

By Sam Boughedda Jefferies analysts initiated Eli Lilly & Co. (NYSE: LLY) with a Hold rating and $290 price target and Merck & Company Inc (NYSE: MRK) with a Buy rating and $125 price target in ...

Eli Lilly closed at $1.87, ranked 34th in trading volume on July 22, 2025. BMO Capital remains bullish, reiterating a buy ...

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Eli Lilly's stock price shot up by 2.89% on a massive trading volume of 21.27 billion, signaling strong investor interest.